Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 41 of 41 publications.

Borker R. Costs associated with adverse events in patients with metastatic renal cell carcinoma. J Med Econ. 2014 Nov;17(11):792-7. doi: 10.3111/13696998.2014.945645

Chen C, Borker R, Ewing J, Tseng WY, Hackshaw MD, Saravanan S, Dhanda R, Nadler E. Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. Sarcoma. 2014 Jan 12;2014:145764. doi: 10.1155/2014/145764

Hagiwara M, Borker R, Oster G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Clin Ther. 2013 Dec;35(12):1955-1963. doi: 10.1016/j.clinthera.2013.10.010

Hess G, Borker R, Fonseca E. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Clin Genitourin Cancer. 2013 Jun;11(2):161-7. doi: 10.1016/j.clgc.2012.10.003

Johnson SJ, Sorg RA, Borker RD, Duh MS. Chemotherapy treatment patterns in elderly patients initially diagnosed with advanced ovarian cancer. Clin Ovarian Other Gynecol Canc. 2012 Dec;5(2):67-77. doi: 10.1016/j.cogc.2013.02.001

Vera-Llonch M, Weycker D, Glass A, Gao S, Borker R, Barber B, Oster G. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy. BMC Health Serv Res. 2011 Nov 10;11:305. doi: 10.1186/1472-6963-11-305

Vera-Llonch M, Weycker D, Glass A, Gao S, Borker R, Qin A, Oster G. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer. 2011 Jun 15;11:250. doi: 10.1186/1471-2407-11-250

Parthan A, Gao SK, Song R, Borker R, Langeberg WJ, Teitelbaum A, Oglesby A. Health care resource utilization (HRU) in advanced ovarian cancer: findings from linked SEER-medicare data. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):PA31.

Gao SK, Boer R, Oglesby A, Lalla A, Yu HT, Langeberg WJ, Calimlim B, Borker R. Treatment patterns in adult patients with metastatic renal cell carcinoma in the United States. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):PA52-A53.

Lage MJ, Borker R, Barger B, Gao S. Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer. J Med Econ. 2010;13(4):691-7. doi: 10.3111/13696998.2010.531829.

Vera-Llonch M, Glass A, Weycker D, Borker R, Gao S, Oster G. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 2009. Orrlando, FL. [abstract] Value Health. 2009 May; 12(3):PA47.

Graham C, Borker R, Oppe M, Groot CD, Barber B, Brogan A, Amado R. Cost-effectiveness of panitumumab plus best supportive care compared with best supportive care alone in chemorefractory metastatic colorectal cancer patients with wild-type KRAS tumor status in the Netherlands. Poster presented at the European Society for Medical Oncology; September 12, 2008. Stockholm, Sweden. [abstract] Ann Oncol. 2008 Sep 12; 19:134.

Graham CN, Borker R, Oppe M, Uyl-de Groot CA, Brogan AJ, Barber B. Cost-effectiveness of panitumumab plus best supportive care (BSC) compared with BSC alone in chemorefractory metastatic colorectal cancer (MCRC) patients (PTS) with wild-type (WT) KRAS tumor status in the Netherlands. Poster presented at the 33rd European Society for Medical Oncology (ESMO) Congress; September 2008.

Ray JA, Borker R, Barber B, Valentine WJ, Belozeroff V, Palmer AJ. Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. Value Health. 2008 Sep;11(5):800-8. doi: 10.1111/j.1524-4733.2008.00329.x

Simon D, Finkelstein F, Barber B, Matza L, Borker R, Malley K. Predictors of disease progression in subjects with stage 3 or 4 CKD. Poster presented at the National Kidney Foundation 2008 Spring Clinical Meeting; April 6, 2008. Dallas, TX. [abstract] Am J Kidney Dis. 2008 Apr; 51(4):PB1-PB27.

Hoy T, Fisher M, Barber B, Borker R, Stolshek B, Goodman W. Adherence to K/DOQI practice guidelines for bone metabolism and disease. Am J Manag Care. 2007 Nov;13(11):620-5.

Shih YCT, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics. 2007 Jul 1;25(7):577-90.

Doan QV, Gleeson M, Kim J, Borker R, Griffiths R, Dubois RW. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Opin. 2007 Jul;23(7):1561-9. doi: 10.1185/030079907x199790

Belozeroff V, Borker R, Barber B, Pupim L, Hakin R. Trends in parathyroid hormone (PTH) in hemodialysis patients. Poster presented at the National Kidney Foundation 2007 Spring Clinical Meeting; April 10, 2007. Orlando, FL. [abstract] Am J Kidney Dis. 2007 Apr; 49(4):PB1-PB24.

Hoy T, Fisher M, Borker R, Barber B, Stolshek B, Goodman W. Adherence to K/DOQI guidelines for bone metabolism & disease in chronic kidney disease. Poster presented at the National Kidney Foundation 2007 Spring Clinical Meeting; April 10, 2007. Orlando, FL. [abstract] Am J Kidney Dis. 2007 Apr; 49(4):PB1-B24.

Doan QV, Dylan M, Griffiths R, Borker R, Barber B, Kim J, Dubois RW. Economic impact of cardiovascular disease and fractures in patients with ESRD. Poster presented at the National Kidney Foundation 2007 Spring Clinical Meeting; April 10, 2007. Orlando, FL. [abstract] Am J Kidney Dis. 2007 Apr; 49(4):PB1-B24.

Ray J, Borker R, Barber B, Valentine W, Belozeeroff V, Palmer A. Cost-effectiveness of treating patients with cinacalcet early versus delaying treatment with cinacalcet for secondary hyperparathyroidism in patients with ESRD. Poster presented at the National Kidney Foundation 2007 Spring Clinical Meeting; April 10, 2007. Orlando, FL. [abstract] Am J Kidney Dis. 2007 Apr; 49(4):PB1-B24.

Simon D, Finkelstein F, Barber B, Matza L, Borker R, Malley K. Comorbidity among patients with chronic kidney disease. Poster presented at the National Kidney Foundation 2007 Spring Clinical Meeting; April 10, 2007. Orlando, FL. [abstract] Am J Kidney Dis. 2007 Apr;.

Delea T, Hagiwara M, Borker R, Stanford R. Observational study of the risk of ED visit or hospitalization in COPD patients receiving maintenance therapies: a time-dependent analysis. Presented at the 71st Annual Chest International Meeting; October 2005. Montreal, Canada. [abstract] Chest. 2005 Oct; 128(4 Supplement):178S. doi: 10.1378/chest.128.4_MeetingAbstracts.178S-a

Borker RD, Watkins M, Knobil K, Emmett A, Kalberg C. Using distribution-based standard error of measurement (SEM) method to determine minimal important difference (MID) for the symptom status index (SSI). Poster presented at the CHEST 2005: 71st Annual Meeting of the American College of Chest Physicians; October 29, 2005. Montreal, Canada. [abstract] Chest. 2005 Oct; 128(4 supplement):251S.

Borker RD, Hayflinger C, Stanford R. Risk of hospitalization/emergency visit in patients with chronic obstructive pulmonary disease by initial medication regimen. Poster presented at the CHEST 2005: 71st Annual Meeting of the American College of Chest Physician; October 2005. [abstract] Chest. 2005 Oct; 128(4 Supplement):257S.

Riedel A, Chastek B, Borker RD. Healthcare and economic burden in undiagnosed chronic obstructive pulmonary disease (COPD) patients. Presented at the 71st Annual Chest International Meeting; October 2005. Montreal, Canada. [abstract] Chest. 2005 Oct; 128(4 Supplement):123S.

Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P. Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. Ann Allergy Asthma Immunol. 2005 Aug;95(2):181-9. doi: 10.1016/S1081-1206(10)61209-4

Borker R, Watkins M, Knobil K, Stanford R, Emmett A, Kalberg C. Psychometric stability of the visual analog scale (VAS) based symptom status index (SSI) in COPD. Poster presented at the ERS International Congress 2005; May 20, 2005. Copenhagen, Germany.

Borker RD, Madhavan SM, Higa G. Assessment of breast cancer knowledge, screening behavior, risk perceptions and willingness to consume chemopreventive agent in women in the West Virginia medicaid program (WVMP). Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 15, 2005. Washington, DC. [abstract] Value Health. 2005 May; 8(3):P348-9.

Borker RD, Madhavan SM, Scott V. Economics of primary and secondary breast cancer preventive strategies:a decision analysis model. Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 15, 2005. Washington, DC. [abstract] Value Health. 2005 May; 8(3):P345.

Rascati KL, Stanford RH, Borker R. A comparison of the risk of hospitalizations due to chronic obstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin Ther. 2005 Mar;27(3):346-54. doi: 10.1016/S0149-2918(05)00052-4

Mauskopf JA, Shih T, Baker T, Borker R, Stanford RH, Jhingran P. Budget impact analysis: combination fluticasone and salmeterol for asthma. Value Health. 2004 Jan 1;7(3):312.

O'Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics. 2004;22(12):815-25. doi: 10.2165/00019053-200422120-00004

Madhavan SS, Borker RD, Fernandes AW, Amonkar MM, Rosenbluth SA. Assessing predictors of influenza and pneumonia vaccination in rural senior adults. J Health Soc Policy. 2004;18(4):13-38. doi: 10.1300/J045v18n04_02

Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results from the Confronting COPD survey. Respir Med. 2003 Mar;97 Suppl C:S81-9. doi: 10.1016/s0954-6111(03)80028-8

Madhavan SS, Rosenbluth SA, Amonkar M, Fernandes A, Borker R. Immunization predictors in rural adults under 65 years of age. J Health Care Poor Underserved. 2003 Feb;14(1):100-21.

Fischer TL, Borker R, Barnhart F, Morris A, Zhu J. Effect of cilomilast on chronic obstructive pulmonary disease (COPD) patients with impaired quality of life (QOL). Presented at the 69th Annual Chest International Meeting; January 2003. Orlando, FL. [abstract] Chest. 2003 Jan; 124(4 Supplement):129S. doi: 10.1378/chest.124.4_MeetingAbstracts.129S

Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics. 2002;20(13):909-18. doi: 10.2165/00019053-200220130-00004

Madhavan SS, Rosenbluth SA, Amonkar M, Borker RD, Richards T. Pharmacists and immunizations: a national survey. J Am Pharm Assoc (Wash). 2001 Jan;41(1):32-45. doi: 10.1016/s1086-5802(16)31203-7

Rosenbluth SA, Madhavan SS, Borker RD, Maine LL. Pharmacy immunization partnerships: a rural model. J Am Pharm Assoc (Wash). 2001 Jan;41(1):100-7. doi: 10.1016/s1086-5802(16)31210-4